Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma
Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma
NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
